FDA approval of Novartis’s Zolgensma made it the primary gene therapy for the rare muscle disorder spinal muscular atrophy. The 2019 regulatory decision also reinforced to the market the premium pricing of a one-time treatment by a genetic medicine—greater than $2.1 million.
The genetic medicines market is taking shape as latest products follow Zolgensma’s footsteps. Recent approvals of recent cell and gene therapies together with coming regulatory decisions for added products are actually pressing payers to regulate to those latest kinds of therapies and the costs they command. Their decisions have implications about who can gain access to those potentially curative and whether paying for them will break the bank.
“They’re really trying to find out do I even have that risk and what can I do to guard myself,” said Raymond Brown, North American practice leader for Mercer, a healthcare consulting firm.
Brown spoke Tuesday in Las Vegas during a HLTH conference session about the fee of cell and gene therapies. He was joined by Nico Economides, principal, health & life sciences, at consulting firm Oliver Wyman.
Many of the cell and gene therapies which were reached the market to date are in cancer and rare disease. But Economides sees the scope of those therapies to broadening soon, addressing more prevalent diseases. For instance, the primary gene therapies for hemophilia (from BioMarin Pharmaceutical) and sickle cell disease (from Bluebird Bio) could reach the market as early as next 12 months. Those upcoming regulatory decisions have insurance firms fascinated by learn how to cover these latest therapies.
Insurance carriers are really trying to grasp the implications of those therapies, including the financial risks, Brown said. In light of the potential for being answerable for paying for these very expensive latest sorts of therapies, payers are in search of ways to guard themselves from the financial costs. Some are weighing what whether or not they need reinsurance or another longer-term strategy, Brown said.
Economides said that in his discussions with carriers, two key concerns have emerged. The primary is the high cost of those therapies, which translates roughly as how can the firm pay for these therapies. The second concern is the sturdiness of those treatments, which translates as whether the therapy is value paying for.
Cell and gene therapies carry high price tags due to curative potential from a one-time treatment. Generally, these therapies are getting covered because they fill a medical need that has no other treatment options, Brown said. Coverage decisions could get trickier as cell and gene therapies expand to more prevalent conditions. Straight away, coverage of cell and gene therapies is sensible under a medical profit, Brown said. But for another indications, the sector could move toward placing them under pharmacy advantages. In such cases, reimbursement could require prior authorization. One indication where that might occur is hemophilia, where patients do have treatment alternatives to a gene therapy, Brown said.
As for the sturdiness of those treatments, uncertainty stays. Brown said a method payers are selecting to guard themselves is outcomes-based reimbursement, alternatively called value-based contracting. These agreements tie the payment to specified outcomes that reveal profit from the treatment, Brown said. Outcomes-based agreements usually are not latest, but for plan sponsors, they’ve been a “nice-to-have” option, Brown said. Now, some therapies have them and others don’t. But Brown sees the high prices of cell and gene therapies creating more demand for demonstration of therapeutic outcomes.
“If these are truly being seen as cures, I believe there’s going to be lots more concentrate on these risk-based agreements,” he said.
Zynteglo, Bluebird Bio’s recently approved gene therapy for beta thalassemia offers a recent example of this approach. Patients who’ve this rare blood disorder require frequent blood transfusions. In clinical trials, measuring transfusion independence was how the advantage of the therapy was assessed. Bluebird set a $2.8 million price that topped Zolgensma, but the corporate can be offering outcomes-based agreements under which a portion of that sum could be repaid if, over time, patients need to return to needing transfusions.
The opposite query payers are asking is learn how to judge risk. Brown noted that not every hemophilia patient will need Roctavian, the BioMarin gene therapy currently under FDA review as a possible one-time treatment for hemophilia A. Considerations transcend diagnosing the disorder. They include accounting for patient history and the severity of the disease. Brown sees payers moving toward authorization strategies. Nevertheless, he adds that there’s not a variety of traction for stop-loss reinsurance, a variety of insurance for the insurance firms. In stop-loss reinsurance, the reinsurer covers the first insurer’s losses incurred in a specified period and as much as a specified amount.
Outcomes-based agreements face a challenge that is exclusive in comparison with health coverage in lots of other countries. Within the U.S., where coverage is especially tied to employment, insureds move from plan to plan as they modify jobs, which could make tracking the therapeutic final result difficult, Brown said. He sees the potential for third parties to enter the space offering ways to trace those outcomes. Despite cell and gene therapies offering potential cures for patients, outcomes-based agreements don’t last ceaselessly, Economides added. These agreements typically include an outlined period for monitoring the patient to evaluate the therapeutic final result.
Photo: BlackJack3D, Getty Images